A Phase 2 Trial of Antisense Nucleotide to PKC-Alpha (LY900003, ISIS 3521) Plus Gemcitabine and Carboplatin in Patients With Advanced, Previously Untreated Non-Small Cell Lung Cancer.
Clinical trial NCT00042679 · COMPLETED
Trial details
- NCT number
- NCT00042679
- Sponsor
- Eli Lilly and Company
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2002-06-01
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.